Merkel Cell Carcinoma Dependence on Bcl-2 Family Members for Survival

Merkel cell carcinoma (MCC), a rare but aggressive cutaneous neoplasm with high metastatic potential, has a poor prognosis at late stages of disease with no proven chemotherapeutic regimens. Using an enriched culture medium, we established and characterized 11 MCC cell lines for Bcl-2 family profili...

Full description

Saved in:
Bibliographic Details
Published inJournal of investigative dermatology Vol. 134; no. 8; pp. 2241 - 2250
Main Authors Verhaegen, Monique E., Mangelberger, Doris, Weick, Jack W., Vozheiko, Tracy D., Harms, Paul W., Nash, Kevin T., Quintana, Elsa, Baciu, Paul, Johnson, Timothy M., Bichakjian, Christopher K., Dlugosz, Andrzej A.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.08.2014
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Merkel cell carcinoma (MCC), a rare but aggressive cutaneous neoplasm with high metastatic potential, has a poor prognosis at late stages of disease with no proven chemotherapeutic regimens. Using an enriched culture medium, we established and characterized 11 MCC cell lines for Bcl-2 family profiling and functional studies. Immunoblot analysis revealed collectively high protein levels of prosurvival Bcl-2 members in cell lines and a panel of MCC tumors. Downregulation of individual Bcl-2 proteins by RNAi promoted death in a subset of MCC cell lines, whereas simultaneous inhibition of multiple family members by using the small-molecule antagonist ABT-263 led to a marked induction of cell death in 10 of 11 lines. ABT-263 induced Bax-dependent apoptosis with rapid cleavage of caspase-3 and PARP, regardless of Bcl-2 family profile or the presence of Merkel cell polyomavirus. Furthermore, ABT-263 treatment led to rapid and sustained growth suppression of MCC xenografts from a representative cell line, accompanied by a striking increase in apoptosis. Our results establish that concurrent inhibition of multiple prosurvival Bcl-2 proteins leads to effective induction of apoptosis, and strongly support the concept that targeting MCC dependence on these molecules may be useful therapeutically by reversing an intrinsic resistance to cell death.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: OncoMed Pharmaceuticals, 800 Chesapeake Drive, Redwood City, CA, 94063 USA
ISSN:0022-202X
1523-1747
DOI:10.1038/jid.2014.138